| Name | BPR1J-097 hydrochloride (1327167-19-0(free base)) |
| Description | BPR1J-097, a new-type small molecule FLT-3 inhibitor(IC50=11±7 nM), is with great anti-tumor activities in vivo. |
| Kinase Assay | Cells are treated with THZ531 for 6 hours.After treatment cells are washed 2-fold with cold PBS and then lysed in the following lysis buffer: Hepes(50 mM, pH 7.4), NaCl（150 mM）, 1% Nonidet P40 substitute, EDTA（5 mM）, DTT（1 mM）, and protease/phosphatase cocktails.Lysates are treated with bio-THZ1 or bio-TH531 for pulldown overnight at 4°C. |
| In vivo | In FLT3-driven AML murine xenograft models, BPR1J-097 inhibited FLT3/signal transducer and activator of transcription 5 phosphorylation and triggered apoptosis in FLT3-driven AML cells and pronounced dose-dependent tumour growth inhibition and regression. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 5.53 mg/mL (10 mM), Sonication is recommended.
|
| Keywords | FLT3 | BPR1J-097 hydrochloride (1327167-19-0(free base)) | BPR-1J-097 hydrochloride (1327167-19-0(free base)) | BPR1J097 hydrochloride (1327167190(free base)) | BPR1J 097 hydrochloride (1327167 19 0(free base)) |
| Inhibitors Related | UNC2025 | Gilteritinib | Nintedanib | Sunitinib | Sunitinib Malate | Sorafenib | Tandutinib | Pexidartinib | KW-2449 | Sorafenib tosylate | SGI-1776 | Fedratinib |
| Related Compound Libraries | Anti-Lung Cancer Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | Angiogenesis related Compound Library | Inhibitor Library | NO PAINS Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
United States
